Prime Medicine, Inc. Related Party Transaction, Expenses from Transactions with Related Party
Prime Medicine, Inc. (PRME) reported Related Party Transaction, Expenses from Transactions with Related Party of $300.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty · last filed 2023-05-11
- Prime Medicine, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2023-03-31 was $300.00K.
- Prime Medicine, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2022-09-30 was $0.00.
- Prime Medicine, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2021-12-31 was $41.74M.
- Prime Medicine, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2021-09-30 was $0.00.
- Prime Medicine, Inc. related party transaction, expenses from transactions with related party for fiscal 2021 was $42.17M, a 28013.33% increase from fiscal 2020.
- Prime Medicine, Inc. related party transaction, expenses from transactions with related party for fiscal 2020 was $150.00K.
| Period end | Related Party Transaction, Expenses from Transactions with Related Party 3 month | Related Party Transaction, Expenses from Transactions with Related Party 6 month | Related Party Transaction, Expenses from Transactions with Related Party 9 month | Related Party Transaction, Expenses from Transactions with Related Party 12 month |
|---|---|---|---|---|
| 2023-03-31 | $300.00K 10-Q · filed 2023-05-11 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||
| 2021-12-31 | $41.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $41.74M derived: sum of 2 quarters · filed 2023-03-09 | $42.17M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $429.00K 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | $150.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |